Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Conference item
Title: Strategic timing of anti-TNF therapy in postoperative Crohn's disease: Comparison of routine use immediately postoperatively with selective use after demonstrated recurrence at 6 month endoscopy. Results from POCER
Author: De Cruz, P.
Kamm, M.
Hamilton, A.
Ritchie, K.
Krejany, S.
Gorelik, A.
Liew, D.
Prideaux, L.
Lawrance, I.
Andrews, J.
Bampton, P.
Sparrow, M.
Florin, T.
Gibson, P.
Debinksi, H.
Gearry, R.
Macrae, F.
Leong, R.
Kronborg, I.
Radford-Smith, G.
et al.
Citation: Journal of Gastroenterology and Hepatology, 2013, vol.28, iss.Suppl. 2, pp.92-92
Publisher: Wiley
Issue Date: 2013
ISSN: 1440-1746
Conference Name: Australian Gastroenterology Week (AGW) (7 Oct 2013 - 9 Oct 2013 : Melbourne, Australia)
Statement of
P De Cruz ... J Andrews ... et al.
Abstract: Introduction: Recent data suggest that anti-TNF therapy prevents post-operative recurrence of Crohn’s disease. Routine postoperative use is costly and may lead to overtreatment; an alternative may be selective use for early endoscopic recurrence. These strategies have been compared with mucosal healing as the goal in this “treat to target” study. Methods: In the Post Operative Crohn’s Endoscopic Recurrence, “POCER” study, after resection patients were stratified for risk of recurrence as high (smoker, perforating disease,≥2nd operation) or low risk. All patients received 3 months metronidazole 400 mg bd. High risk patients also received daily azathioprine 2 mg/kg or 6 mercaptopurine 1.5 mg/kg, or adalimumab 40 mg fortnightly if thiopurine intolerant. Patients were randomised to endoscopy at 6 months or no endoscopy; endoscopic remission defined as Rutgeerts score i0 or i1 & recurrence as≥i2. For endoscopic recurrence at 6 months high risk patients on thiopurine stepped up to adalimumab 40 mg fortnightly, & high risk thiopurine-intolerant patients stepped up to weekly adalimumab. All patients were colonoscoped at 18months: the primary endpoint endoscopic recurrence. In this intent-to-treat sub-analysis we compared the 18 month outcomes of high risk patients in the endoscopy arm on immediate postoperative adalimumab to those initially on thiopurine who stepped-up to combined adalimumab+thiopurine for recurrence at 6 months. Results: Endoscopic recurrence at 18 months occurred in 12/28 (43%)patients on adalimumab immediately postoperatively compared to19/32 (59%) patients initially on thiopurine who stepped up to adalimumab+thiopurine at 6 months; P=0.20. Complete mucosal normality (i0) occurred in 9/28 (32%) v 7/32 (22%); P=0.37. Severe disease(i3 & i4) occurred in 3/28 (11%) v 3/32 (9%); P=NS. Conclusions: Recurrence did not differ significantly between immediate postoperative adalimumab & step-up adalimumab at 6 months for endoscopic recurrence, although the former tended to be more effective. There was minimal difference in rates of severe disease recurrence between the two strategies. Step-up with anti-TNF therapy based on endoscopic findings is a viable postoperative strategy in patients at high risk of recurrence.
Rights: © 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd
DOI: 10.1111/jgh.12365_6
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.